| Literature DB >> 35250381 |
Atakan Tanacan1, Seyit Ahmet Erol1, Ali Taner Anuk1, Fatma Didem Yucel Yetiskin1, Eda Ozden Tokalioglu1, Selin Sahin1, Serpil Unlu2, Huseyin Levent Keskin3, Aziz Ahmet Surel4, Ozlem Moraloglu Tekin3, Dilek Sahin3.
Abstract
Introduction To evaluate the association of serum electrolytes with disease severity and obstetric complications in pregnant women with Coronavirus disease 2019 (COVID-19). Materials and Methods This prospective cohort study was conducted on pregnant women with confirmed COVID-19. Study population was divided into two groups: 1) Mild COVID-19 group (n = 811) and 2) Moderate/severe COVID-19 group (n = 52). Demographic features, clinical characteristics, obstetric complications, and serum electrolytes were compared between the groups. Afterward, a correlation analysis was performed to investigate the association between serum electrolyte disturbances with COVID-19 severity and obstetric complications. Results Highest serum sodium, hypernatremia, potassium replacement, hypopotassemia, hyperchloremia, initial serum magnesium, hypermagnesemia, and hypocalcemia were significantly higher in the moderate/severe COVID-19 group. The lowest serum sodium, lowest serum potassium, and initial serum calcium were significantly higher in the mild COVID-19 group (p < 0.05). Statistically significant positive weak correlations were found between hypernatremia, hypopotassemia, hyperchloremia, hypermagnesemia, hypocalcemia and COVID-19 severity (r values were 0.27, 0.20, 0.12, 0.18 and 0.12, p values were < 0.001, < 0.001, 0.02, 0.03 and 0.03, respectively). Furthermore, statistically significant positive weak correlations were found between hypopotassemia, hypochloremia, hypermagnesemia, and obstetric complications (r values were 0.10, 0.10, and 0.28, p values were 0.004, 0.03, and 0.001, respectively). A statistically significant negative weak correlation was found between hypomagnesemia and obstetric complications (r = - 0.23 and p = 0.01, respectively). Conclusion Electrolyte disturbances in pregnant women with COVID-19 seem to be associated with disease severity and obstetric complications. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).Entities:
Keywords: COVID-19; disease severity; electrolytes; obstetric complications; pregnancy
Year: 2022 PMID: 35250381 PMCID: PMC8893987 DOI: 10.1055/a-1577-3249
Source DB: PubMed Journal: Geburtshilfe Frauenheilkd ISSN: 0016-5751 Impact factor: 2.915
Table 1 Comparison of demographic features and clinical characteristics between mild COVID-19 group and moderate/severe COVID-19 group.
| Variables | Mild infection group (n = 811) | Moderate/severe infection group (n = 52) | p value |
|---|---|---|---|
| BMI: Body mass index, COVID-19: Coronavirus disease 2019, DM: Diabetes mellitus, FGR: Fetal growth restriction, GDM: Gestational diabetes mellitus, GHT: Gestational hypertension,
ICU: Intensive care unit, IHCP: Intrahepatic cholestasis of pregnancy, IQR: Inter-quartile range, PPROM: Preterm premature rupture of membranes | |||
| Maternal age (years) (median, IQR) a | 28 (8) | 29 (12) | 0.08 |
| BMI (kg/m 2 ) (median, IQR) a | 25.9 (6) | 23.9 (8) | 0.11 |
| Gravidity (median, IQR) a | 2 (2) | 2 (2) | 0.62 |
| Parity (median, IQR) a | 1 (2) | 1 (2) | 0.83 |
| Maternal comorbidity (n, %) b | 185 (22.8%) | 15 (28.8%) | 0.41 |
Obesity (n, %) (BMI ≥ 30 kg/m 2 ) b | 73 (9%) | 3 (5.7%) | |
Hypothyroidism (n, %) | 37 (4.5%) | 1 (1.9%) | |
Hypertension (n, %) | 34 (4.2%) | 2 (3.8%) | |
DM (n, %) | 15 (1.8%) | 5 (9.6%) | |
Asthma (n, %) | 10 (1.2%) | 2 (3.8%) | |
Renal disease (n, %) | 3 (0.3%) | 1 (1.9%) | |
Other (n, %) | 13 (1.6%) | 1 (1.9%) | |
| Gestational age at diagnosis (weeks) (median, IQR) a | 27 (19) | 26 (18.25) | 0.32 |
| Pregnancy trimester at diagnosis (n, %) b | 0.87 | ||
First | 193 (23.8%) | 13 (25%) | |
Second | 261 (32.1%) | 18 (34.6%) | |
Third | 357 (44.1%) | 21 (40.4%) | |
| Oxygen support (n, %) b | 12 (1.5%) | 35 (67.3%) |
|
| ICU admission (n, %) b | 0 (0%) | 12 (23.1%) |
|
| Radiologic findings (n, %) b | 42 (5.2%) | 19 (36.5%) |
|
| Hydroxychloroquine (n, %) b | 70 (8.6%) | 16 (30.7%) |
|
| Lopinavir-ritonavir (n, %) b | 34 (4.2%) | 21 (40.4%) |
|
| Azithromycin (n, %) b | 16 (1.9%) | 4 (7.7%) |
|
| Systemic corticosteroid (n, %) b | 21 (2.6%) | 26 (50%) |
|
| Low-molecular weight heparin (n, %) b | 337 (41.5%) | 42 (80.7%) |
|
| Anakinra (n, %) b | 3 (0.3%) | 10 (19.2%) |
|
| Convalescent plasma (n, %) b | 11 (1.3%) | 15 (28.8%) |
|
| Antenatal corticosteroid therapy (n, %) b | 7 (0.8%) | 5 (9.6%) |
|
| Maternal mortality (n, %) b | 0 (0%) | 3 (5.7%) |
|
| Obstetric complications (n, %) b | 79 (9.7%) | 14 (26.9%) |
|
Miscarriage (n, %) | 12 (1.4%) | 2 (3.8%) | |
Preterm labor (n, %) | 25 (3%) | 4 (7.7%) | |
GDM (n, %) | 6 (0.7%) | 2 (3.8%) | |
GHT (n, %) | 7 (0.8%) | 2 (3.8%) | |
Preeclampsia (n, %) | 6 (0.7%) | 1 (1.9%) | |
FGR (n, %) | 7 (0.8%) | 1 (1.9%) | |
PPROM (n, %) | 8 (0.9%) | 1 (1.9%) | |
IHCP (n, %) | 8 (0.9%) | 1 (1.9%) | |
Table 2 Comparison of serum electrolyte values between mild COVID-19 and moderate/severe COVID-19 group.
| Variables | Mild infection group (n = 811) | Moderate/severe infection group (n = 52) | p value |
|---|---|---|---|
| COVID-19: Coronavirus disease 2019, IQR: Inter-quartile range | |||
| Initial serum sodium (mEq/l) (median, IQR) a | 138 (3) | 138 (4) | 0.79 |
| Highest serum sodium (mEq/l) (median, IQR) a | 139 (3) | 141 (3) |
|
| Lowest serum sodium (mEq/l) (median, IQR) a | 138 (3) | 137 (3) |
|
| Sodium replacement (n, %) b | 0 (0%) | 1 (1.9%) | 0.07 |
| Hypernatremia (n, %) b | 0 (0%) | 4 (7.7%) |
|
| Hyponatremia (n, %) b | 69 (8.5%) | 6 (11.5%) | 0.63 |
| Initial serum potassium (mEq/l) (median, IQR) a | 4 (0.5) | 3.9 (0.6) | 0.11 |
| Highest serum potassium (mEq/l) (median, IQR) a | 3.8 (0.75) | 3.7 (0.75) | 0.53 |
| Lowest serum potassium (mEq/l) (median, IQR) a | 3.8 (0.4) | 3.6 (0.6) |
|
| Potassium replacement (n, %) b | 18 (2.2%) | 8 (15.3%) |
|
| Hyperpotassemia (n, %) b | 0 (0%) | 1 (1.9%) | 0.16 |
| Hypopotassemia (n, %) b | 99 (12.2%) | 21 (40.4%) |
|
| Initial serum chloride (mEq/l) (median, IQR) a * | 107 (2) | 108 (3) | 0.06 |
| Hypochloremia (n, %) b | 1/365 (0.2%) | 0/47 (0%) | 0.72 |
| Hyperchloremia (n, %) b | 17/365 (4.6%) | 6/47 (12.7%) |
|
| Initial serum magnessium (mg/dl) (median, IQR) a * | 1.7 (0.3) | 1.8 (0.3) |
|
| Hypomagnesemia (n, %) b | 61/115 (53.1%) | 6/18 (33.3%) | 0.12 |
| Hypermagnesemia (n, %) b | 2/115 (1.7%) | 2/18 (11.1%) |
|
| Initial serum calcium (mg/dl) (median, IQR) a * | 8.8 (0.7) | 8.7 (0.6) |
|
| Hypocalcemia (n, %) b | 200/343 (58.3%) | 36/47 (76.6%) |
|
| Hypercalcemia (n, %) b | 2/343 (0.6%) | 0/47 (0%) | 0.59 |
Table 3 Correlation of serum electrolyte disturbances with COVID-19 severity and obstetric complications.
| Parameter | COVID-19 severity | Obstetric complications | ||
|---|---|---|---|---|
| r value a | p value a | r value a | p value a | |
| COVID-19: Coronavirus disease 2019 | ||||
| Hyponatremia | 0.02 | 0.46 | 0.04 | 0.24 |
| Hypernatremia | 0.27 |
| 0.03 | 0.35 |
| Hypopotassemia | 0.20 |
| 0.10 |
|
| Hyperpotassemia | 0.27 | 0.17 | 0.25 | 0.21 |
| Hypochloremia | − 0.02 | 0.72 | 0.10 |
|
| Hyperchloremia | 0.12 |
| − 0.03 | 0.56 |
| Hypomagnesemia | − 0.13 | 0.12 | − 0.23 |
|
| Hypermagnesemia | 0.18 |
| 0.28 |
|
| Hypocalcemia | 0.12 |
| − 0.04 | 0.41 |
| Hypercalcemia | − 0.03 | 0.59 | 0.05 | 0.27 |